Premium Nahrungsergänzungsmittel | artgerecht

GlycA – Inflammatory Biomarker Explained

GlycA is a novel composite biomarker of systemic inflammation measured by NMR spectroscopy, reflecting chronic inflammatory activity and long-term disease risk.

Regular tips about health Regular tips about health

Things worth knowing about "GlycA"

GlycA is a novel composite biomarker of systemic inflammation measured by NMR spectroscopy, reflecting chronic inflammatory activity and long-term disease risk.

What is GlycA?

GlycA (also written as GlykA) is a composite inflammatory biomarker measured from a blood sample using nuclear magnetic resonance (NMR) spectroscopy. The GlycA signal originates from the carbohydrate (glycan) side chains of specific acute-phase proteins that rise during inflammation, including alpha-1-acid glycoprotein, haptoglobin, alpha-1-antitrypsin, alpha-1-antichymotrypsin, and transferrin. GlycA is considered an integrated measure of chronic systemic inflammatory activity.

Background and Significance

Traditional inflammatory markers such as C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR) are highly sensitive to acute events and can fluctuate widely. GlycA, by contrast, reflects a more stable, longer-term picture of the body's inflammatory burden -- analogous to how HbA1c reflects average blood glucose levels over time. This makes GlycA particularly useful for assessing the risk of chronic diseases.

Clinical Relevance and Applications

GlycA has been studied extensively as a predictor of risk for a range of conditions:

Cardiovascular disease: Elevated GlycA levels are associated with a higher risk of heart attack, stroke, and cardiovascular death.
Type 2 diabetes: GlycA is linked to insulin resistance and the development of type 2 diabetes.
Chronic inflammatory diseases: Conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are associated with elevated GlycA.
Metabolic syndrome: GlycA correlates with obesity, dyslipidemia, and other components of metabolic syndrome.
Cancer: Preliminary research suggests a link between elevated GlycA and increased cancer risk.

Measurement and Interpretation

GlycA is measured exclusively by NMR spectroscopy, the same technology used to determine lipoprotein subfractions (e.g., LDL particle size and number). The measurement requires only a standard blood draw. GlycA values are reported in μmol/L.

Reference Values

In the general population, GlycA values typically range between 300 and 500 μmol/L. Values above 400–450 μmol/L are associated with elevated cardiovascular and metabolic risk in multiple large studies. Since GlycA is not yet a standard clinical laboratory test, universally accepted cut-off values have not been established.

Factors That Influence GlycA Levels

Several lifestyle and health factors can affect GlycA concentrations:

Diet: An anti-inflammatory diet (e.g., the Mediterranean diet) is associated with lower GlycA levels.
Physical activity: Regular exercise is linked to reduced GlycA.
Smoking: Tobacco use elevates GlycA levels.
Obesity: Excess body weight is frequently associated with higher GlycA values.
Medications: Statins and certain anti-inflammatory drugs may reduce GlycA.
Acute infections: Can cause a temporary, sharp rise in GlycA.

Advantages Over Traditional Inflammatory Markers

Compared to CRP or interleukin-6 (IL-6), GlycA offers several advantages:

GlycA is more stable and less susceptible to short-term fluctuations.
It reflects medium-term inflammatory burden over weeks to months.
As a composite marker, it simultaneously captures multiple acute-phase proteins.
GlycA can provide additional prognostic information even when CRP levels appear normal.

Current Research and Outlook

While GlycA is not yet a standard parameter in routine clinical diagnostics, it is gaining increasing importance in preventive medicine and research. Major population studies, including the Framingham Heart Study and the MESA cohort, have confirmed GlycA as an independent predictor of cardiovascular events. In the future, GlycA may become part of expanded preventive medicine blood panels.

References

Connelly, M. A. et al. - GlycA: A new biomarker for inflammation and cardiovascular disease risk. Journal of Clinical Lipidology, 2016.
Duprez, D. A. et al. - Comparison of the predictive value of GlycA and other biomarkers of inflammation for the long-term risk of cardiovascular disease. Journal of the American Heart Association, 2016.
Wang, Z. J. et al. - GlycA, a novel biomarker of inflammatory glycoproteins, is associated with risk of incident diabetes and cardiovascular events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.